To the Editor.
—That the principal investigators in the two recent studies1,2 of tacrine are employees of and hold stock options in Parke-Davis Pharmaceutical Research Division of Warner-Lambert Co represents a glaring and hopeless conflict of interest. I believe that this accounts for the overall favorable tone of the articles' conclusions, despite the overwhelming evidence that tacrine is a grossly hepatotoxic drug with unpleasant side effects.I am grateful that JAMA's editorial policy requires disclosure of such financial interests, but it is disturbing that the accompanying Editorial ignored them. I believe that these articles should not have been printed in a peer-reviewed journal.
Temianka D. Tacrine for Alzheimer's Disease. JAMA. 1994;272(24):1896-1897. doi:10.1001/jama.1994.03520240024022